172 related articles for article (PubMed ID: 38228620)
1. Optimizing drug combination and mechanism analysis based on risk pathway crosstalk in pan cancer.
Hu C; Mi W; Li F; Zhu L; Ou Q; Li M; Li T; Ma Y; Zhang Y; Xu Y
Sci Data; 2024 Jan; 11(1):74. PubMed ID: 38228620
[TBL] [Abstract][Full Text] [Related]
2. Quantifying Risk Pathway Crosstalk Mediated by miRNA to Screen Precision drugs for Breast Cancer Patients.
Xu Y; Lin S; Zhao H; Wang J; Zhang C; Dong Q; Hu C; Desi S; Wang L; Xu Y
Genes (Basel); 2019 Aug; 10(9):. PubMed ID: 31466383
[TBL] [Abstract][Full Text] [Related]
3. Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways.
Tang J; Karhinen L; Xu T; Szwajda A; Yadav B; Wennerberg K; Aittokallio T
PLoS Comput Biol; 2013; 9(9):e1003226. PubMed ID: 24068907
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive overview of oncogenic pathways in human cancer.
Li F; Wu T; Xu Y; Dong Q; Xiao J; Xu Y; Li Q; Zhang C; Gao J; Liu L; Hu X; Huang J; Li X; Zhang Y
Brief Bioinform; 2020 May; 21(3):957-969. PubMed ID: 31155677
[TBL] [Abstract][Full Text] [Related]
5. A novel dysregulated pathway-identification analysis based on global influence of within-pathway effects and crosstalk between pathways.
Han J; Li C; Yang H; Xu Y; Zhang C; Ma J; Shi X; Liu W; Shang D; Yao Q; Zhang Y; Su F; Feng L; Li X
J R Soc Interface; 2015 Jan; 12(102):20140937. PubMed ID: 25551156
[TBL] [Abstract][Full Text] [Related]
6. Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data.
Xu Y; Dong Q; Li F; Xu Y; Hu C; Wang J; Shang D; Zheng X; Yang H; Zhang C; Shao M; Meng M; Xiong Z; Li X; Zhang Y
J Transl Med; 2019 Aug; 17(1):255. PubMed ID: 31387579
[TBL] [Abstract][Full Text] [Related]
7. TranSynergy: Mechanism-driven interpretable deep neural network for the synergistic prediction and pathway deconvolution of drug combinations.
Liu Q; Xie L
PLoS Comput Biol; 2021 Feb; 17(2):e1008653. PubMed ID: 33577560
[TBL] [Abstract][Full Text] [Related]
8. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles.
Li X; Xu Y; Cui H; Huang T; Wang D; Lian B; Li W; Qin G; Chen L; Xie L
Artif Intell Med; 2017 Nov; 83():35-43. PubMed ID: 28583437
[TBL] [Abstract][Full Text] [Related]
9. Predicting Potential Drugs for Breast Cancer based on miRNA and Tissue Specificity.
Yu L; Zhao J; Gao L
Int J Biol Sci; 2018; 14(8):971-982. PubMed ID: 29989066
[TBL] [Abstract][Full Text] [Related]
10. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of computational methods for identifying miRNA-mediated RNA-RNA crosstalk.
Li Y; Jin X; Wang Z; Li L; Chen H; Lin X; Yi S; Zhang Y; Xu J
Brief Bioinform; 2019 Jul; 20(4):1193-1204. PubMed ID: 29077860
[TBL] [Abstract][Full Text] [Related]
12. p73-Governed miRNA Networks: Translating Bioinformatics Approaches to Therapeutic Solutions for Cancer Metastasis.
Logotheti S; Marquardt S; Pützer BM
Methods Mol Biol; 2019; 1912():33-52. PubMed ID: 30635889
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics Methods for Modeling microRNA Regulatory Networks in Cancer.
Pan T; Gao Y; Xu G; Li Y
Adv Exp Med Biol; 2022; 1385():161-186. PubMed ID: 36352214
[TBL] [Abstract][Full Text] [Related]
14. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
15. Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.
Bashi AC; Coker EA; Bulusu KC; Jaaks P; Crafter C; Lightfoot H; Milo M; McCarten K; Jenkins DF; van der Meer D; Lynch JT; Barthorpe S; Andersen CL; Barry ST; Beck A; Cidado J; Gordon JA; Hall C; Hall J; Mali I; Mironenko T; Mongeon K; Morris J; Richardson L; Smith PD; Tavana O; Tolley C; Thomas F; Willis BS; Yang W; O'Connor MJ; McDermott U; Critchlow SE; Drew L; Fawell SE; Mettetal JT; Garnett MJ
Cancer Discov; 2024 May; 14(5):846-865. PubMed ID: 38456804
[TBL] [Abstract][Full Text] [Related]
16. ncDRMarker: a computational method for identifying non-coding RNA signatures of drug resistance based on heterogeneous network.
Yang H; Xu Y; Shang D; Shi H; Zhang C; Dong Q; Zhang Y; Bai Z; Cheng S; Li X
Ann Transl Med; 2020 Nov; 8(21):1395. PubMed ID: 33313140
[TBL] [Abstract][Full Text] [Related]
17. Identifying novel associations between small molecules and miRNAs based on integrated molecular networks.
Lv Y; Wang S; Meng F; Yang L; Wang Z; Wang J; Chen X; Jiang W; Li Y; Li X
Bioinformatics; 2015 Nov; 31(22):3638-44. PubMed ID: 26198104
[TBL] [Abstract][Full Text] [Related]
18. Network Propagation Predicts Drug Synergy in Cancers.
Li H; Li T; Quang D; Guan Y
Cancer Res; 2018 Sep; 78(18):5446-5457. PubMed ID: 30054332
[TBL] [Abstract][Full Text] [Related]
19. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies.
Xu J; Regan-Fendt K; Deng S; Carson WE; Payne PRO; Li F
Pac Symp Biocomput; 2018; 23():92-103. PubMed ID: 29218872
[TBL] [Abstract][Full Text] [Related]
20. Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities.
Di J; Zheng B; Kong Q; Jiang Y; Liu S; Yang Y; Han X; Sheng Y; Zhang Y; Cheng L; Han J
Mol Oncol; 2019 Oct; 13(10):2259-2277. PubMed ID: 31408580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
